Vous l’avez sûrement remarqué : notre boutique se pare d’un tout nouveau look frais et moderne ! Notre nom, logo et site ont été repensés, mais rassurez-vous : nous restons la même librairie et papeterie que vous connaissez et appréciez.
Curieux·euse de découvrir l’histoire derrière notre nouveau style ?
This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox.
Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area.
The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.
Nous publions uniquement les avis qui respectent les conditions requises. Consultez nos conditions pour les avis.
